Expression of survivin has been reported to be correlated with shorter survival in patients with non-small cell lung cancer (NSCLC), and overexpression of survivin may lead to radioresistance in various human cancers. In this study, we inhibited survivin expression by using an adenoviral vector (AdsiSurvivin)-mediated RNA interference to elucidate the combined effect of survivin-targeting gene therapy and radiotherapy on the NSCLC cells. Our data showed that AdsiSurvivin exerted survivin gene silencing, induced apoptosis, and significantly attenuated the growth potential in NSCLC cells within 72 h after infection. The combined treatment modalities with AdsiSurvivin infection and radiation were significantly more potent on cell-growth inhibition than monotherapy. In H1650, H460, A549, and H1975 human NSCLC cells, the survival ratios of AdsiSurvivin-treated groups at multiplicity of infection of 25 and 50 were significantly lower than those of control groups at varying radiation dose (0-8 Gy; three-way analysis of variance, Po0.05). The cytotoxicity of combined AdsiSurvivin infection and irradiation increased in a dose-dependent manner in both the virus and the irradiation treatment. Knockdown of the survivin gene expression seems to be a promising treatment strategy for NSCLC. Our data warrant the need for further effort to develop survivin-targeted radiosensitizer for lung cancer treatment.
Introduction
Survivin is a member of the inhibitor of apoptosis family that acts as a suppressor of apoptosis and has a critical role in tumor initiation, progression, and drug resistance. 1 High levels of survivin have been found in most human cancers, including cancers of the lung, colon, pancreas, prostate, breast, and stomach. [2] [3] [4] [5] Expression of survivin has been reported to be correlated with shorter survival in patients with non-small cell lung cancer (NSCLC). 3 Survivin is expressed in the G 2 /M phase in a cell-cycleregulated manner, and its interaction with the microtubules of mitotic spindle at the beginning of mitosis is essential for its anti-apoptotic function. Disruption of the survivin-microtubules interaction results in the loss of survivin's anti-apoptotic function and increases the caspase-3 activity. 6, 7 Overexpression of survivin has oncogenic potential because it may overcome the G 2 /M-phase checkpoint to compel the cell cycle to progress through mitosis. 6 In addition, survivin overexpression has been shown to result in accelerated S-phase shift, resist G 1 arrest, activate cyclin-dependent kinase 2/cyclin E complex and thereby result in Rb phosphorylation. 8 Moreover, the expression of survivin could be significantly upregulated by a sublethal dose of irradiation, which might cause radioresistance. 9 Lu et al. 10 reported that overexpression of survivin in human embryonic kidney cells (293 cells) prevented irradiation-induced apoptosis and increased cell viability after irradiation. Increasing evidences indicated that the expression of survivin correlated with radioresistance in various cancers, thereby implying that survivin may be a potential target for radiosensitization during cancer treatment. [11] [12] [13] [14] Radiotherapy is commonly used in NSCLC treatment for either curative or palliative purposes. However, majority of patients are most likely to suffer regional failure as a part of their disease recurrence process. 15, 16 Recent researches to improve the clinical outcome in such patients include altered irradiation fraction schedule and the introduction of chemotherapy, biotherapy, immunotherapy, virotherapy, or gene therapy on a concurrent or adjuvant basis. [17] [18] [19] [20] [21] [22] Survivin gene expression has been identified in a majority of NSCLC. 3 Additionally, Tamm et al. 23 reported that among all the human tumor cells screened, lung cancer cells expressed the highest levels of survivin. As survivin overexpression may lead to resistance to radiotherapy by inhibiting apoptosis and enhancing cell viability, knockdown of the survivin gene expression by RNA interference should be a promising approach to ameliorate the efficacy of radiotherapy during NSCLC treatment. In this study, we inhibited survivin expression by using RNA interference to elucidate the combined effect of survivin-targeting gene therapy and radiotherapy on NSCLC cells. To achieve sufficiently high level of gene suppression in adequately large numbers of target cells, we constructed an adenoviral vector expressing short hairpin RNA (shRNA). 24 We show here the impact of adenovirus-mediated transfer of small interfering RNA (siRNA) targeting survivin on human NSCLC cells and the additive efficacy with irradiation in cell killing.
Materials and methods

Cell lines
The NSCLC cell lines A549 (ATCC CCL-185), H460 (ATCC HTB-177), H1650 (ATCC CRL-5883), and H1975 (ATCC CRL-5908) were purchased from American Type Culture Collection (ATCC; Manassas, VA, US). All were cultured in Dulbecco's modified eagle medium (DMEM) complete media containing 10% fetal bovine serum.
Development of stable 293 cell lines with high survivin expression PcDNA3-survivin plasmid was constructed by subcloning the fragment of the survivin-encoding cDNA from plasmid pORF5-hSurvivin (Invivogene, San Diego, CA) into the pcDNA3-flag at BamHI site. The vector of pcDNA3-flag was the same as described earlier. 25 Human embryonic kidney cells (E1-transformed; 293 cells) were subsequently transfected with pcDNA3-survivin; transfection was conducted by using a liposome-mediated transfection technique with lipofectamine 2000 reagent (Invitrogen, Grand Island, NY) and in accordance with the manufacturer's protocol. The transfected cells were replated at a 1:20 dilution in DMEM complete media containing 10% fetal bovine serum and 1000 mg ml À1 neomycin (G418; Gibco-BRL Life Technologies Inc., Rockville, MD), and cultured for 14 days with the replacement of the selective media every 3-4 days. The surviving transfectants that were localized in distinct 'islands' were then maintained with the growth medium. Then, real-time PCR was used to screen the survivin expression of individual clones. The stable cell lines with high survivin expression, namely 293S cells, were used for further experiments.
Adenoviral vectors
A 19 nt survivin-targeting sequence of oligonucleotides was designed by Oligoengine Inc. (Seattle, WA) and selected as the template: TTCGTCCGGTTGCGCTTTC. By the basic local alignment search tool (BLAST) analysis, it was confirmed that the template shared no homology with other coding sequences in human beings. A linkage sequence of six base pairs (ATCGAT) existed between the sense and antisense strands. Plasmid pUC-U6, which was kindly gifted by Dr Tang (College of Agriculture and Natural Resources, National Chung Hsing University, Taiwan), was derived from pUC-18 (Fermentas, Burlington, ON, Canada) and contained the U6 promoter inserted between the XhoI and the KpnI sites. The shRNA expression cassette was subcloned into pUC-U6 between the KpnI and the XbaI sites. Then, the XhoI-HindIII fragment containing the tandem arranged U6 promoter-driven shRNA expression cassette was double enzyme cut by restriction endonucleases and ligated to the pAdTrack vector. 26 The resultant plasmid was linearized by digesting with restriction endonuclease, and subsequently cotransformed to Escherichia coli BJ5183 cells with an adenoviral backbone plasmid, pAdEasy-1. 26 Recombinants were selected for kanamycin resistance, and recombination was confirmed by restriction endonuclease analysis. The linearized recombinant plasmid was then transduced into the 293 cells. A recombinant adenovirus expressing shRNA against survivin (AdsiSurvivin) was generated. The recombinant adenovirus AdCtrl, which carries a green fluorescence protein gene regulated by the cytomegalovirus promoter, was constructed with pAdTrack and pAdEasy-1, and used as the control in these experiments. 27, 28 These adenovirus vectors were amplified by using the 293S cells, and titered by using both Adeno-X Rapid Titer kit (BD Biosciences, San Jose, CA) and 293S cells.
Real-time quantification of survivin-targeted siRNA by stem-loop RT-PCR For survivin-targeted siRNA quantification, a pulsed reverse transcription (RT) reaction as described by Chen et al. 29 was performed to convert all microRNAs into corresponding cDNAs in one RT reaction. Briefly, 10 ml reaction mixture containing siRNA-specific stem-loop RT primers (5 0 -CTCAACTGGTGTCGTGGAGTCGGCA ATTCAGTTGAGGAAAGCGC-3 0 , final 2 mM each), 500 mM dNTP, 0.5 ml Superscript III (InVitrogen, Carlsbad, CA), and 1 mg total RNA was used for the RT reaction. The pulsed RT reaction was performed as follows: 16 1C for 30 min, followed by 50 cycles at 20 1C for 30 s, 42 1C for 30 s, and 50 1C for 1 s. RT products were diluted 20-folds before using for siRNA quantitative PCR (Q-PCR). Then, 1 ml of diluted RT product was used as template for a 10 ml PCR. Briefly, 1 Â SYBR Master Mix (Applied Biosystem, Foster City, CA), 200 nM siRNA-specific forward primer (5 0 -CGGCGGTTCGT CCGGTTGCGCT -3 0 ), and 200 nM universal reverse primer (5 0 -CTGGTGTCGTGGAGTCGGCAATTC-3 0 ) were used for each PCR. The condition for Q-PCR was 95 1C for 10 min, followed by 40 cycles at 95 1C for 15 s and at 63 1C for 32 s, and a dissociation stage. End point reaction products were analyzed on a 10% polyacrylamide gel stained with ethidium bromide to discriminate between the correct amplification product (57-60 bp) and the potential primer dimmers (o44 bp). All Q-PCR reactions were performed on an ABI Prism 7500 Fast Real-Time PCR system (Foster City, CA). 6 ) were plated onto 10 cm dishes and incubated for 16 h at 37 1C before infection. They were subsequently mock infected or infected with either AdCtrl or AdsiSurvivin, and incubated for 24-96 h. Total cell lysates from the infected cells were extracted with lysis buffer (M-PER Mammalian Protein Extraction Reagent; Thermo Fisher Scientific Inc., Rockford, IL). The primary antibodies used were mouse antisurvivin monoclonal antibody (2802; Cell Signaling Technology, Boston, MA), goat anti-g tubulin polyclonal antibody (sc-7396; Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit anti-poly-(ADP-ribose) polymerase (PARP) polyclonal antibody (9542; Cell Signaling Technology). Horseradish peroxidase-conjugated goat anti-mouse, goat anti-rabbit, or donkey anti-goat antibody were used as the secondary antibody (Santa Cruz Biotechnology). Chemiluminescence detection was carried out by using ECL Plus (GE Healthcare, Piscataway, NJ) and executed according to the manufacturer's instructions. ) were plated onto 10 cm dishes, incubated for 16 h at 37 1C, then mock infected or infected with either AdCtrl or AdsiSurvivin (m.o.i. of 50 each). Five days after the infection, the cells were collected by trypsinization, washed twice with 0.1% glucose in PBS without Mg þ þ or Ca þ þ (sample buffer), and then fixed in ice-cold 70% ethanol overnight at 4 1C. Subsequently, the cells were centrifuged for 5 min at 1500 r.p.m. After decanting the 70% ethanol without disturbing the pellet, the cells were stained with 50 mg ml À1 propidium iodide, 100 U ml À1 RNase A in a sample buffer. The samples were subsequently analyzed by two-dimensional flow cytometry (Epics Ultra, Beckman Coulter, Fullerton, CA) to detect propidium iodide. The cell cycles were determined by EXPO32 ADC analysis software. (10, 25 , and 50) and varying radiation doses with the treatment of AdsiSurvivin or AdCtrl. Two-way ANOVA was used to analyze the data acquired over time from both the treatment groups. The first factor was the treatment (AdsiSurvivin vs AdCtrl groups), and the second factor was time (days 3-5). Tukey's honestly significant difference (HSD) test was used for pair-wise comparisons. A P value of 0.05 or less indicated significant statistical difference.
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Results
Survivin expression after treatment with AdsiSurvivin
We generated stable 293S cell lines containing cytomegalovirus promoter-controlled survivin expression. As illustrated in Figure 1 , the expression of survivin in 293S cells was strongly detected by using immunoblotting analysis; further, the expression was markedly higher than that observed in the 293 cells. We used the 293S cells to amplify and titer the adenoviral vector expressing shRNA against survivin. By using the AdEasy system, we generated an adenoviral vector, AdsiSurvivin, which carries both shRNA expression cassette for silencing of survivin gene and the green fluorescence protein gene under control of the U6 promoter and cytomegalovirus promoter, respectively. AdCtrl, which is similar to AdsiSurvivin except that it lacks the U6 promoter-driven Figure 3 ). The numbers of viable cells in the AdCtrlinfected group were lower than those of the mock-infected cells for all the cell lines, which indicates the cytotoxicity from the expressed viral proteins and the overexpression of green fluorescence protein. [30] [31] [32] The tested cell lines had different sensitivities to this virus-related toxicity. At m.o.i. of 50, the ratios of viable cell numbers in the AdCtrl-treated group to those in the mock-infected group (survival ratio) were not less than 50% (50.0 ± 3.09, 64.2±1.89, 65.6±2.83, and 65.8±1.17%, respectively) and the ratios of viable cell numbers in the AdsiSurvivintreated group to those in the AdCtrl-infected group were not more than 50% (25.6 ± 0.02, 24.5 ± 0.02, 6.15 ± 0.01, and 49.1±0.03%, respectively) in H460, A549, H1975, and H1650 cells. Additionally, 48 h after infection with AdsiSurvivin or AdCtrl at m.o.i. of 50, nearly 100% of cells expressed the green fluorescent protein, which was Figure 4 , the growth of AdsiSurvivin-infected cells was substantively suppressed by survivin gene silencing. Day 3 onwards, the numbers of viable cells in the AdsiSurvivin-infected groups were significantly lower than those in the AdCtrl-infected groups in the H460, A549, and H1650 cell lines (P ¼ 0.0022, 0.00005, and 0.00056, respectively). The H1975 cells seemed more vulnerable to AdsiSurvivin treatment. The number of viable AdsiSurvivin-infected H1975 cells was significantly less than that infected with AdCtrl since day 2 (P ¼ 0.0257; Figure 4d ). The cytotoxicity of AdsiSurvivin was significantly more potent than that of AdCtrl from days 3 to 5 in all the four cell lines (two-way ANOVA, Po0.05 in four comparisons).
Apoptosis induced by AdsiSurvivin treatment
To assess the apoptosis induced by survivin inhibition, the A549, H1650, H460, and H1975 cells were treated with mock infection, or either AdsiSurvivin or AdCtrl at m.o.i. of 50. On day 5 after the infection, cell-cycle analysis showed marked increase in the subG1 population of the AdsiSurvivin-treated cells (Figure 5a ). To confirm the presence of the apoptotic process, the four cell lines were also treated with either AdsiSurvivin or AdCtrl at m.o.i. of 50; we then examined the cleavage of PARP by western blot analysis. Day 3 onwards, degradation of PARP was clearly detected only in the AdsiSurvivin-treated cells, but not in the AdCtrl-infected cells (Figure 5b) . The above findings indicated that survivin inhibition by siRNA induced programed cell death, which was accompanied by the increased protein cleavage for PARP, in all four NSCLC cell lines.
Effects of concurrent treatments of the NSCLC cells with AdsiSurvivin and radiation
We then investigated the cytotoxicity because of the combined effects of radiation and survivin inhibition on the NSCLC cells. The H1650, H460, A549, and H1975 lung cancer cells were treated with AdsiSurvivin or AdCtrl at m.o.i. of 10, 25, or 50. The culture medium alone was used for mock infection. These cells were subsequently treated with radiation at 0, 2, 4, or 8 Gy 48 h after infection. Triplet cultures for each combination treatment were counted for the detection of any viable cells on day 3 after the radiation, that is, day 5 after infection. As shown in Figure 6 , increase in the radiation dose significantly decreased the survival ratio in a dosedependent manner in the AdCtrl-infected groups at m.o.i. of 10, 25, and 50 in all the four cell lines (three-way ANOVA, Po0.05 in all the 12 comparisons). In H460, A549, and H1975 cells, the survival ratios of AdsiSurvivin-treated groups at m.o.i. of 10, 25, and 50 were significantly lower than those of the AdCtrl-treated groups at varying radiation doses (three-way ANOVA, Po0.05 in all the nine comparisons; Figures 6b-d) . At m.o.i. of 10, there were no significant differences in the survival ratios between AdsiSurvivin and AdCtrl-infected groups in the H1650 cells concurrently treated with radiation at varying doses (three-way ANOVA, P ¼ 0.3571; Figure 6a ). Although the viral dose increased to m.o.i. of 25 and 50, the survival ratios of the AdsiSurvivin-infected H1650 cells were significantly lower than those of the AdCtrl-infected cells concurrently treated with radiation at varying doses (three-way ANOVA, Po0.05 in both comparisons; Figure 6a ). When combined with the treatment of AdsiSurvivin at high dose (m.o.i. of 50), irradiation-induced cell killing did not occur in a dose-dependent pattern in both the H1650 and A549 cells. The survival ratio was significantly higher in nonirradiated A549 cells than when treated with irradiation at 2 Gy (21.62±4.35% vs 16.22±1.35%, P ¼ 0.002) in high-dose AdsiSurvivin-infected groups; however, there were no significant differences between 2 and 4 Gy or 2 and 8 Gy radiation (P40.05 in both the comparisons, Figure 6c ). In H1650 cells treated with AdsiSurvivin at m.o.i. of 50, the survival ratio of the nonirradiated cells was not significantly different from those irradiated with 2 or 4 Gy (P40.05 in both comparisons, Figure 6a) ; however, at 8 Gy, there was a significant difference between the nonirradiated and irradiated H1650 cells (28.7±0.86% vs 13.27±1.14%, P ¼ 0.000046).
Discussion
NSCLC is the leading cause of cancer-related deaths worldwide. Unfortunately, standard therapies remain inadequate for attaining disease control. The conventional chemotherapy regimens and radiotherapy are more of a hindrance because of their limited efficacy, significant toxicity, the development of resistance, and high relapse rates; this warrants the need for newer therapeutic approaches. More recently, modest success has been achieved using novel agents to target signaling transduction pathways, growth factor receptors, oncogenes, and tumor-suppressor genes, which are known to become aberrant in lung cancer. 33 For example, the epidermal growth factor receptor tyrosine kinase inhibitors are a major advancement in lung cancer treatment. 34, 35 However, the eventual development of acquired resistance in the responders also hampers the clinical benefit of these agents during NSCLC treatment. 36 Therefore, further studies targeting multiple treatment modalities and/or the inhibition on multiple signaling pathways are required in our efforts to develop a novel therapeutic strategy to enhance anticancer efficacy and/or prevent drug resistances. Owing to the high expression level in NSCLC and significant clinical association with survival outcome and treatment resistance, survivin has been widely evaluated as a potential therapeutic target for radiation sensitization in lung cancer. By using antisense oligonucleotides, several studies have shown the potential of survivin inhibition on sensitizing lung cancer cells to radiation. 10, 37 To achieve such a radiosensitization, we combined gene transfer by adenoviral vector and RNA interference technology to improve the efficacies of both gene transduction and expression inhibition in the NSCLC cells. Uchida et al. 38 used adenovirus-mediated transfer of siRNA against survivin to induce apoptosis and attenuate tumor cell growth in HeLa, U251, and MCF-7 cells. However, our preliminary data showed that replication of AdsiSurvivin resulted in marked survivin gene silencing and cell death in both 293 and 293T cells (ATCC CRL-11268), which resulted in the failure of the virus yield (data not shown). Therefore, we generated 293S cells to overcome this toxicity and succeeded in constructing and amplifying AdsiSurvivin for further studies. However, the yield of AdsiSurvivin is only 10% of AdCtrl despite using 293S cells for viral amplification. In this study, our data showed that AdsiSurvivin successfully exerted survivin gene silencing, induced apoptosis, and significantly attenuated the growth potential in NSCLC cells. These effects may set in early within 72 h after infection. Furthermore, the effect of combined treatment modalities including AdsiSurvivin infection and radiation is significantly more potent on cell-growth inhibition than monotherapy involving either one of the above. This additive effect was noted even at low virus dose (m.o.i. of 10) in most of the cells that were tested. The cytotoxicity of combined AdsiSurvivin infection and irradiation increased in a dose-dependent manner for both the treatment modalities. However, the increase in radiation dose during concurrent treatment with high dose (m.o.i. of 50) of AdsiSurvivin did not increase cell death in A549 and H1650 cells. It should be because of the superiority of AdsiSurvivin to irradiation in cytotoxicity at high viral dose.
We show that the adenovirus-mediated transfer of siRNA against survivin may enhance the radiosensitivity of human NSCLC cells. Owing to this additive efficacy of survivin gene knockdown and irradiation on cell death in NSCLC, this combined treatment modality has the potential to improve the anticancer efficacy and/or thus reduce radiation dose to attenuate collateral damage to normal tissue if applied clinically. Our data warrant the need for further effort to develop survivin-targeted radiosensitizer for NSCLC treatment.
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